Epinephrine in neonatal resuscitation: dose, route, timing

Newborn cardiac arrest almost always stems from profound hypoxia and respiratory failure, not primary cardiac disease. Because of that physiology, epinephrine does nothing without aerated lungs. Under the NRP 9th Edition and 2025 AHA/AAP Guidelines, epinephrine is indicated only after at least 30 seconds of effective positive-pressure ventilation (PPV) that visibly moves the chest, followed by 60 seconds of chest compressions coordinated 3:1 with ventilation in 100% oxygen, with the heart rate still lagging below 60 beats per minute (bpm).

Dose and concentration: exact calculations

During cardiac arrest, epinephrine's primary job is alpha-1 mediated vasoconstriction. Clamping down systemic arterioles raises aortic diastolic pressure, driving oxygenated blood into the coronary arteries so the myocardium can recover spontaneous contractility. Beta-1 stimulation helps increase heart rate and inotropy once coronary perfusion is restored.

Because volumes in preterm infants can be as small as 0.1 mL, drawing up the medication correctly prevents critical dosing errors:

Draw IV or IO doses into a 1 mL syringe to allow measurement down to 0.01 mL, and label it Epinephrine-IV. For endotracheal bridge doses, draw the volume into a 3 mL or 5 mL syringe and label it Epinephrine-ET ONLY. Never push an ET-labeled syringe through an intravenous or intraosseous line.

Route: why IV and IO access are preferred over ETT

The vascular route delivers medication straight to the central circulation where compressions can propel it to the coronary arteries. In the delivery room, an emergency umbilical venous catheter (UVC) is the fastest access: insert a 3.5F catheter (preterm) or 5F catheter (term) roughly 2 to 4 cm into the umbilical vein just until you get free blood return. Stop advancing as soon as blood aspirates to keep the tip low in the vein, avoiding accidental wedging in the ductus venosus or liver parenchyma. Follow every IV or IO dose with a rapid 3 mL normal saline flush.

If UVC placement stalls or the cord is torn, an intraosseous (IO) needle placed in the proximal tibia is an effective alternative. Do not spend time searching for peripheral IVs; in severe shock, collapsed peripheral vessels cause extravasation and delay life-saving drugs.

Think of the endotracheal (ETT) route strictly as a temporary bridge. Epinephrine absorption across the pulmonary epithelium is slow and unpredictable, which is why the ETT dose is 5 times higher (0.1 mg/kg = 1.0 mL/kg). Give an ETT dose only while another team member is actively placing a UVC or IO needle; never delay vascular access to repeat ETT doses.

Timing, reassessment, and refractory bradycardia

Re-evaluate the heart rate 1 minute after administering IV or IO epinephrine. The heart rate should rise to 60 bpm or higher within 60 seconds of an effective dose.

Repeat epinephrine every 3 to 5 minutes if the heart rate stays below 60 bpm. If you started at the initial 0.02 mg/kg dose without adequate response, you can consider stepping up subsequent doses within the 0.01 to 0.03 mg/kg range.

When the heart rate remains below 60 bpm despite epinephrine and compressions, step back and evaluate reversible causes:

First, re-verify effective lung aeration. Check bilateral chest movement, tube depth at the gum line, and color change on the CO₂ detector. An unrecognized tube displacement or airway obstruction stops resuscitation progress immediately.

Second, audit CPR quality. Ensure compressions depress the lower third of the sternum by one-third of the chest depth, allow complete recoil, and maintain the 3:1 rhythm (90 compressions and 30 breaths per minute).

Third, evaluate for hypovolemic shock. When there is a history of blood loss (such as placental abruption, vasa previa, or umbilical cord disruption) or physical signs of hypovolemia (pale appearance, weak pulses, delayed capillary refill), administer a volume expander: 10 mL/kg of Normal Saline or type O Rh-negative red blood cells via slow IV or IO push over 5 to 10 minutes.